我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2000
进行中（未招募）
1
50.0%
已完成
暂无批准数据
- ValiRx PLC announced that Ambrose Healthcare Ltd has exercised its option to license VAL401, a reformulated risperidone with anti-cancer properties, for up to £16 million plus royalties. - VAL401 represents a drug repurposing approach, utilizing the established anti-psychotic drug risperidone which has demonstrated anti-cancer effects in preclinical studies. - The licensing agreement includes milestone payments totaling £16 million plus royalties, with Ambrose committing to complete development and commercialization of the asset. - ValiRx plans to leverage its subsidiary's 19 pancreatic patient-derived cell models for preclinical validation, utilizing 3D systems supported by FDA guidance for investigational new drug submissions.
